| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,890,000 |
| Market
Cap: |
36.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.51 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
124,000 |
250,000 |
502,000 |
544,000 |
| Total Sell Value |
$248,524 |
$732,545 |
$2,303,135 |
$2,608,163 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
5 |
12 |
30 |
34 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ball Bryan |
See remarks |
• – – |
2024-04-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,000 |
|
- |
|
| Desai Neil |
EXECUTIVE CHAIRMAN |
• • – |
2024-04-02 |
4 |
AS |
$2.23 |
$49,513 |
I/I |
(22,228) |
1,371,543 |
|
-20% |
|
| Desai Neil |
EXECUTIVE CHAIRMAN |
• • – |
2024-04-01 |
4 |
AS |
$2.31 |
$41,101 |
I/I |
(17,772) |
1,393,771 |
|
-24% |
|
| Desai Neil |
EXECUTIVE CHAIRMAN |
• • – |
2024-03-04 |
4 |
AS |
$2.10 |
$31,415 |
I/I |
(14,964) |
1,411,543 |
|
-28% |
|
| Desai Neil |
EXECUTIVE CHAIRMAN |
• • – |
2024-03-01 |
4 |
AS |
$1.97 |
$53,226 |
I/I |
(27,036) |
1,426,507 |
|
-9% |
|
| Desai Neil |
Executive Chairman |
• • – |
2024-02-01 |
4 |
AS |
$1.74 |
$73,269 |
I/I |
(42,000) |
1,453,543 |
|
-1% |
|
| Desai Neil |
Executive Chairman |
• • – |
2024-01-02 |
4 |
AS |
$2.06 |
$86,549 |
I/I |
(42,000) |
1,495,543 |
|
-15% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-12-06 |
4 |
AS |
$4.82 |
$33,914 |
I/I |
(7,037) |
1,537,543 |
|
-62% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-12-05 |
4 |
AS |
$5.02 |
$78,941 |
I/I |
(15,740) |
1,544,580 |
|
-64% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-12-04 |
4 |
AS |
$5.15 |
$55,986 |
I/I |
(10,876) |
1,560,320 |
|
-63% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-12-01 |
4 |
AS |
$5.14 |
$42,881 |
I/I |
(8,347) |
1,571,196 |
|
-61% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-11-02 |
4 |
AS |
$4.46 |
$141,105 |
I/I |
(31,662) |
1,579,543 |
|
-55% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-11-01 |
4 |
AS |
$4.32 |
$44,645 |
I/I |
(10,338) |
1,611,205 |
|
-50% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-10-03 |
4 |
AS |
$4.10 |
$67,303 |
I/I |
(16,431) |
1,621,543 |
|
-53% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-10-02 |
4 |
AS |
$4.37 |
$111,698 |
I/I |
(25,569) |
1,637,974 |
|
-57% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-09-06 |
4 |
AS |
$5.29 |
$37,637 |
I/I |
(7,111) |
1,663,543 |
|
-69% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-09-05 |
4 |
AS |
$5.63 |
$118,316 |
I/I |
(21,000) |
1,670,654 |
|
-69% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-09-01 |
4 |
AS |
$5.97 |
$82,873 |
I/I |
(13,889) |
1,691,654 |
|
-71% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-08-02 |
4 |
AS |
$5.20 |
$100,250 |
I/I |
(19,290) |
1,705,543 |
|
-6% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-08-01 |
4 |
AS |
$5.22 |
$118,523 |
I/I |
(22,710) |
1,724,833 |
|
-9% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-07-06 |
4 |
AS |
$6.27 |
$99,273 |
I/I |
(15,829) |
1,747,543 |
|
-27% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-07-05 |
4 |
AS |
$6.55 |
$105,873 |
I/I |
(16,171) |
1,763,372 |
|
-32% |
|
| Desai Neil |
Executive Chairman |
• • – |
2023-07-03 |
4 |
AS |
$6.64 |
$66,446 |
I/I |
(10,000) |
1,779,543 |
|
-30% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-06-06 |
4 |
AS |
$8.19 |
$59,453 |
I/I |
(7,260) |
1,789,543 |
|
-48% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-06-05 |
4 |
AS |
$8.11 |
$140,418 |
I/I |
(17,315) |
1,796,803 |
|
-48% |
|
138 Records found
|
|
Page 1 of 6 |
|
|
0.07 (4.17%) 
